Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196044 | 0.91 | NAMPT (0.33) | PTGDR2NAMPTHTR6CCKARDHODH | |
| SCHEMBL2194515 | 0.90 | PTGDR2 (0.32) | PTGDR2NAMPTGRM4HTR6CCKAR | |
| SCHEMBL1830275 | 0.89 | HTR2C (0.34) | PTGDR2NAMPTGRM4 | |
| SCHEMBL2413180 | 0.88 | HTR6 (0.37) | NAMPTHTR6SLC6A9 | |
| SCHEMBL1830277 | 0.88 | PTGDR2 (0.34) | PTGDR2NAMPTGRM4CCKAR | |
| SCHEMBL5002808 | 0.84 | HTR6 (0.36) | PTGDR2NAMPTHTR6SLC6A9 | |
| SCHEMBL1831984 | 0.84 | NAMPT (0.34) | NAMPTGRM4PDE4BHTR6NOS2 | |
| SCHEMBL5008217 | 0.84 | HTR6 (0.38) | PTGDR2HTR6 | |
| SCHEMBL2194090 | 0.84 | PTGDR2 (0.33) | PTGDR2NAMPTHTR6CCKARDHODH | |
| SCHEMBL2193027 | 0.84 | NAMPT (0.35) | PTGDR2NAMPTGRM4PDE4BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8592597-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2318390-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056577-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | PTGDR2 387/4885NAMPT 1814/4885GRM4 2678/4885 |
| US-20140031393-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | PTGDR2 387/4885NAMPT 1814/4885GRM4 2678/4885 |
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | PTGDR2 387/4885NAMPT 1814/4885GRM4 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.